Pulmonology

Systemic sclerosis

Questions discussed in this category

What are some important considerations for use of ACE inhibition in scleroderma renal crisis patients who require dialysis?

For example, is captopril dialyzable?

1 Answer available

What would be your recommendation for treatment of worsening lung disease in a patient with long-standing scleroderma after long-term mycophenolate therapy which is no longer an option due to side effect/intolerance?

3 Answers available

What protective post-op measures do you recommend for a patient with scleroderma and a history of ILD, PH, Raynaud’s and digital ischemia undergoing cardiothoracic surgery?

1 Answer available

How do you approach the management of SSc-ILD in a patient on immune checkpoint therapy?

1 Answer available

How will you use tocilizumab in the treatment algorithm for SSc-ILD, given its recent FDA approval?

1 Answer available

Is there a role for anti-IL6 therapy in SSc-associated ILD?

1 Answer available

What is the role of nintedanib in the treatment of SSc-ILD?

The SENSCIS trial was published in 2019 on efficacy of this agent. However, it's not clear where this should be in the treatment algorithm: Monot...

2 Answers available

Papers discussed in this category

N. Engl. J. Med., 2019 May 20

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.

The Lancet. Respiratory medicine, 2016-09

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial.

The New England journal of medicine, 2006-06-22

Cyclophosphamide versus placebo in scleroderma lung disease.

Lancet Respir Med, 2020 Aug 28

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial.

Arthritis Rheumatol, 2021 Feb 03

Tocilizumab Prevents Progression of Early Systemic Sclerosis Associated Interstitial Lung Disease.

Related Topics in Pulmonology